So now that Pattersons paper is being published, how can this directly affect our current share price short term and long term. Are there doctors waiting for this study, and if so, what can they do with the information now that it has been reviewed as reliable? I think its great that leronlimab is the focus of his paper, but don't understand the direct benefit. Thanks for any clarification!